Actively Recruiting
Study of Cord Blood-derived CAR-NK Cells Targeting CD19 for Treating Refractory or Relapsed B-cell Non-Hodgkin Lymphoma in Adults
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-03-04
48
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and early effectiveness of cord blood-derived CAR-NK cells that target CD19 in patients with refractory or relapsed B-cell non-Hodgkins lymphoma NHL. This open, single-arm, dose-escalation phase 1 trial plans to enroll 9 to 18 patients initially to determine the best dose, followed by an additional 30 patients treated with that dose to further assess safety and efficacy. The main focus is on dose-limiting toxicities and overall response rates, including complete and partial responses, overall survival, and progression-free survival. Participants receive a single intravenous infusion of the investigational CB CAR-NK019 cells at one of several dose levels ranging from 2 million to 4 million cells per kilogram. After dose escalation identifies the recommended dose, more patients will receive this dose to better understand treatment effects. The study monitors patients closely for adverse effects and responses up to two years after treatment. During the study, participants will undergo regular evaluations including physical exams, tumor tissue testing for CD19 expression, organ function tests, and imaging studies to assess tumor size and response. Researchers will track safety outcomes such as dose-limiting toxicity within 28 days, and long-term measures like progression-free survival and overall survival for up to two years. Pregnancy tests and COVID-19 tests are also conducted as part of safety monitoring. Overall participation may last up to two years with ongoing follow-up visits.
CONDITIONS
Brief Title
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Research Team
W
Wenbin Qian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here